PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

Take every opportunity to speak with appropriate adult patients about pneumococcal vaccination

Pharmacy Engagement Opportunities

Based on IMS Data from 2012 to 2014, patients aged 50 years or older visited their pharmacists
more frequently than their physicians.19

They visit their physician’s office on average 3.5 times a year, but they pick up prescriptions in a pharmacy up to 15 times a year.19

Pharmacy Engagement Opportunities
Actor portrayal.

As their pharmacist, your recommendation plays an important role in helping protect your patients against pneumococcal disease20

According to a survey of 600 adults aged 35 years of age and oldera:

  • Only 27% of patients are likely to ask their pharmacist about a vaccine for pneumonia/pneumococcal disease.
  • 45% of respondents were likely to accept a pharmacist’s recommendation for a vaccine against pneumonia/pneumococcal disease.
  1. aStudy Design: 2017 Consumer Attitude and Awareness Tracker for PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent); 600 men and women aged 35 to 64 years of age with one or more chronic conditions (diabetes mellitus, chronic heart disease, and chronic lung disease) and 65+ years of age; 20–25 min online survey with national panel; fielded June 26 to September 24, 2017.

Your Recommendation Matters

Consider 4 key phrases to provide a clear vaccination recommendation based on the patient’s medical and pneumococcal vaccination history:

  1. “Pneumococcal disease can be serious.”
    1. Help patients understand that pneumococcal disease is caused by certain types of bacteria and includes pneumococcal infections of the lung, blood, and coverings of the brain and spinal cord.
  2. “Because of your age (65 or older), you might need to receive a second pneumococcal vaccines.”
    1. Make sure that your patients understand that even if they already had a dose of another vaccine for pneumococcal pneumonia and are aged 65 years or older, the CDC recommends that they get PNEUMOVAX 23.1
  3. PNEUMOVAX 23 can help protect against 23 common strains of pneumococcal bacteria that cause pneumococcal disease.”
    1. Explain that PNEUMOVAX 23 vaccine contains 23 different pneumococcal strains and is recommended by the CDC for adults aged 65 years and older as part of a sequential 2-vaccine regimen.1
  4. “I recommend you get this vaccine.”
    1. Your patients trust you as a health care provider—tell them why you recommend this vaccination.
ref1

Reference

  1. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR. 2019;68(46):1069–1075.
ref19

Reference

  1. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1163180-0002.
ref20

Reference

  1. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package VACC-1246827-0001.
ref5

Reference

  1. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822–825.
ref6

Reference

  1. Centers for Disease Control and Prevention (CDC). Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944–947. (Erratum Notice: CDC. MMWR Morb Mortal Wkly Rep. 2015;64(42):1204.)

Indication for PNEUMOVAX 23

PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.
Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Do not administer PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

Available human data from clinical trials of PNEUMOVAX 23 in pregnancy have not established the presence or absence of a vaccine-associated risk.

Since elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and/or a greater severity of reactions in some older individuals cannot be ruled out.

Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.

PNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.

The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 in clinical trials, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.

For subjects aged 65 years or older in a clinical study, systemic adverse reactions which were determined by the investigator to be vaccine-related were higher following revaccination than following initial vaccination.

Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

Before administering PNEUMOVAX 23, please read the accompanying Prescribing Information. The Patient Information also is available.

PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.


US-PNX-00807 02/20